Evidence map›Paper›PMID 37776441›Full record

ArticleApplied biochemistry and biotechnology2024

Screening of Phytocompounds for Identification of Prospective Histone Deacetylase 1 (HDAC1) Inhibitor: An In Silico Molecular Docking, Molecular Dynamics Simulation, and MM-GBSA Approach.

Kaushik Kumar Bharadwaj, Iqrar Ahmad, Siddhartha Pati, Arabinda Ghosh, Bijuli Rabha, Tanmay Sarkar, Dorothy Bhattacharjya, Harun Patel, Debabrat Baishya

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Frontiers in cellular and infection microbiology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kaushik Kumar BharadwajDepartment of Bioengineering and Technology, Gauhati University, Guwahati, 781014, Assam, India.
Iqrar AhmadDivision of Computer Aided Drug Design, Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, 425405, Maharashtra, India.
Siddhartha PatiSkills Innovation & Academic Network (SIAN) Institute-ABC, Balasore, 756001, Odisha, India.
Arabinda GhoshMicrobiology Division, Department of Botany, Gauhati University, Guwahati, Assam, India, 781014.
Bijuli RabhaDepartment of Bioengineering and Technology, Gauhati University, Guwahati, 781014, Assam, India.
Tanmay SarkarDepartment of Food Processing Technology, Malda Polytechnic, West Bengal State Council of Technical Education, Government of West Bengal, Malda, 732102, West Bengal, India.ORCID http://orcid.org/0000-0003-3869-1604
Dorothy BhattacharjyaDepartment of Bioengineering and Technology, Gauhati University, Guwahati, 781014, Assam, India.
Harun PatelDivision of Computer Aided Drug Design, Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, 425405, Maharashtra, India.
Debabrat BaishyaDepartment of Bioengineering and Technology, Gauhati University, Guwahati, 781014, Assam, India. drdbaishya@gmail.com.ORCID http://orcid.org/0000-0002-2929-8539

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The upregulation of HDAC1 facilitate the induction of epigenetic repression of genes responsible for suppressing tumourigenesis, thereby triggering the development of cancer. HDAC1 inhibitors have thus emerged as possible therapeutic approaches against a variety of human malignancies, as they can inhibit the activity of certain HDACs, repair the overexpression of tumour suppressor genes, and induce cell differentiation, cell cycle arrest, and apoptosis. In this study, among 810 virtually screened compounds, Pinocembrin (PHUB000396) had a significant binding affinity (-7.99 kcal/mol). In molecular dynamics simulation (MD) studies for 200 ns time scale, the compound Pinocembrin effectively undergoes conformational optimization, thereby enabling its accommodation within the active site of the receptor. This outcome serves as a rational for the observed binding affinity. The optimal binding free energy calculations using the Molecular Mechanics Generalized Born Surface Area (MM-GBSA) (-35.86 ± 7.52 kcal/mol) showed the significant role of van der Waals forces and Coulomb interactions in the stability of the respective complex. The pharmacokinetic study showed its potential as a lead compound. The in-silico cytotoxicity prediction also confirmed its potential as an active anticancer phytocompound in lung and brain cancer. Therefore, it can be predicted that Pinocembrin could be a useful bioactive compound as an HDAC1 inhibitor and could be used in developing epigenetic therapy in cancer such as brain cancer and lung cancer to regulate gene expression.

Indexed as

Histone Deacetylase 1Histone Deacetylase InhibitorsMolecular Docking SimulationMolecular Dynamics SimulationDrug Evaluation, PreclinicalFlavanonesHumansPhytochemicalsFlavanonesHDAC1 protein, humanHistone Deacetylase 1Histone Deacetylase InhibitorsPhytochemicalspinocembrinADMEAnti-cancerBioactive compoundMolecular dockingMolecular dynamics simulationPhytocompounds

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.